Precision BioSciences Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $19.79M Beat $6.58M Estimate
Portfolio Pulse from Benzinga Newsdesk
Precision BioSciences (NASDAQ:DTIL) reported Q2 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.23) by 56.52%. This is a 78.26% increase over losses from the same period last year. The company also reported quarterly sales of $19.79 million, beating the analyst consensus estimate of $6.58 million by 200.74%. This is a 418.04% increase over sales from the same period last year.
August 04, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision BioSciences reported better than expected Q2 results with losses per share and sales beating analyst estimates.
Precision BioSciences reported Q2 losses per share of $(0.10), which is better than the analyst consensus estimate of $(0.23). This is a significant improvement over the same period last year. The company also reported sales of $19.79 million, significantly beating the analyst consensus estimate of $6.58 million. This strong financial performance could lead to a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100